Lee, Philip
Kistler, Kristin D.
Douyon, Luc
Volodarsky, Raisa
Young, Alex
Karve, Sudeep
Challagulla, Swetha
Funding for this research was provided by:
Pharmacyclics
Article History
Accepted: 4 September 2022
First Online: 19 December 2022
Declarations
:
: PL, RV, AY, SK, and SC conceptualized the study. All authors contributed to the study design. KDK and LD conducted the literature search, data extraction, initial summary of results, and quality assessment. All authors contributed to data interpretation and development of the article, including figures, tables, and electronic supplementary material. All authors approved the final version of the article.
: This study was sponsored and funded by Pharmacyclics LLC, an AbbVie Company.
: Not applicable.
: Not applicable.
: PL: former employment with Pharmacyclics LLC, an AbbVie Company, current employment with Neurocrine Biosciences; travel expenses from Celgene and Novartis; KDK and LD: employment with Xcenda, LLC; research funding from Pharmacyclics LLC, an AbbVie Company; RV, AY, and SC: employment with Pharmacyclics LLC, an AbbVie Company; stock ownership in AbbVie; SK: employment with AbbVie; stock ownership in AbbVie.
: Not applicable.
: Not applicable.
: Not applicable.